高盛发表报告，调整对科伦博泰生物-B(06990.HK) 目标价，由226.32元调整至226.52元，维持“买入”评级。
该行指出，药物SKB264于今年将为全年商业化的第一年。管理层重申对今年表现强劲有信心，指引为全年销售8亿至10亿元人民币。纵使首年商业化会面对挑战，如向医生推广及不包括于国家报销药品清单，但认为该药在推出首年有成功机会，基于具竞争力定价及良好设计的商业团队。
该行下调(收窄)对公司2024年至2026年每股亏损预测，由0.5元至4.3元人民币，降至0.1元至2.6元人民币，反映SKB264药物今年销售指引，调整销售提速趋势预测，以及近期乐品开发进展。(fc/da)(港股报价延迟最少十五分钟。沽空资料截至 2025-01-17 16:25。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.